Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis

Purpose

The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study.

Condition

  • Generalized Myasthenia Gravis

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Completion of a qualifying zilucoplan study

Exclusion Criteria

  • With the exception of a prior zilucoplan trial, participation in another concurrent clinical trial involving an experimental therapeutic intervention (participation in observational studies and/or registry studies is permitted)

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
0.3 mg/kg zilucoplan (RA101495)
  • Drug: zilucoplan (RA101495)
    Daily subcutaneous (SC) injection

More Details

Status
Active, not recruiting
Sponsor
UCB Biopharma SRL

Study Contact